CPA
INO icon

Clear Point Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Clear Point Advisors’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31
Closed -$179 – 318
2024
Q3 		$179 Hold
31
– – ﹤0.01% 535
2024
Q2 		$250 Hold
31
– – ﹤0.01% 524
2024
Q1 		$430 Hold
31
– – ﹤0.01% 504
2023
Q4 		$191 Buy
+31
New +$153 ﹤0.01% 518

Other funds holding INO

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Clear Point Advisors's INO Position: Q4 2024 in Review

Clear Point Advisors sold out of Inovio Pharmaceuticals (INO) in Q4 2024, closing a stake of 31 shares — an estimated $179 sold.

Clear Point Advisors first reported a position in INO in Q4 2023 and held it in 4 quarters. The position peaked at $430 in Q1 2024. 104 funds tracked by Wall St. Rank hold INO as of Q4 2024.

  • Clear Point Advisors reported no remaining Inovio Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Clear Point Advisors sold 31 Inovio Pharmaceuticals shares in Q4 2024, an estimated $179.
  • Clear Point Advisors first reported a position in Inovio Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Clear Point Advisors's Inovio Pharmaceuticals position peaked at $430 in Q1 2024.
  • 104 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2024.

Based on Clear Point Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.